Table 5.
Univariate analysis of the survival rates according to risk factors.
| N (%) | 5-Year DSS (SE) |
p Value | 5-Year LRFS (SE) |
p Value | 5-Year DMFS (SE) |
p Value | |
|---|---|---|---|---|---|---|---|
| CI 95% | CI 95% | CI 95% | |||||
|
Sex Male |
21 (32.8%) | 93.7% (6.05) | 0.6005 | 87.8% (8.06) | 0.6817 | 89.6% (6.97) | 0.8820 |
| Female | 43 (67.2%) | 87.4% (6.27) | 0.08208 to 3.380 | 95.2% (3.32) | 0.2480 to 15.72 | 86.1% (5.85) | 0.1691 to 3.967 |
|
Age <55 |
27 (42.2%) | 89.7% (7.12) | 0.6979 | 95.6% (4.25) | 0.3797 | 87.2% (6.94) | 0.8222 |
| ≥55 | 37 (57.8%) | 90.4% (5.30) | 0.1392 to 4.715 | 89.4% (5.85) | 0.05438 to 2.772 | 87.3% (6.02) | 0.2075 to 4.080 |
|
Age <65 |
37 (57.8%) | 91.5% (6.11) | 0.3045 | 97.3% (2.66) | 0.2313 | 89.9% (5.57) | 0.3433 |
| ≥65 | 27 (42.2%) | 87.3% (6.88) | 0.07859 to 2.769 | 86.3% (7.38) | 0.03230 to 1.726 | 83.6% (7.57) | 0.1194 to 2.410 |
|
Age <70 |
47 (73.4%) | 90.6% (5.45) | 0.3591 | 93% (3.90) | 0.7700 | 90.1% (4.76) | 0.3074 |
| ≥70 | 17 (26.6%) | 86.9% (8.72) | 0.06908 to 3.843 | 91.6% (7.97) | 0.1183 to 9.988 | 79.4% (10.73) | 0.08367 to 2.501 |
|
Age <75 |
54 (84.4%) | 91.8% (4.80) | 0.0681 | 93.9% (3.39) | 0.7534 | 88.8% (4.76) | 0.1956 |
| ≥75 | 10 (15.6%) | 77.1% (14.41) | 0.02013 to 3.058 | 83.3% (15.21) | 0.03079 to 8.227 | 78.7% (13.40) | 0.04801 to 3.441 |
|
Histology Low risk |
46 (70.8%) | 92.8% (5.04) | 0.0254 | 97.8% (2.15) | 0.0296 | 91.6% (4.67) | 0.0229 |
| High risk | 19 (29.2%) | 81.4% (9.86) | 0.02859 to 1.668 | 77% (11.89) | 0.01058 to 1.044 | 76.2% (10.635) | 0.04568 to 1.390 |
|
Neck metastases No |
54 (83.1%) | 95.8% (2.90) | 0.0218 | 98.1% (1.86) | 0.0019 | 96.3% (2.59) | 0.0003 |
| Yes | 11 (16.9%) | 59.6% (19.81) | 0.01163 to 1.387 | 64.2% (16.79) | 0.0037 to 0.914 | 51.1% (15.77) | 0.01037 to 0.577 |
|
PNI No |
47 (72.3%) | 93.9% (4.35) | 0.0301 | 95.2% (3.31) | 0.1328 | 92.4% (4.28) | 0.0141 |
| Yes | 18 (27.7%) | 76.9% (12.10) | 0.02069 to 1.526 | 83.3% (11.19) | 0.02270 to 2.921 | 72.4% (12.208) | 0.03418 to 1.251 |
|
LVI No |
58 (89.2%) | 94.7% (3.85) | <0.0001 | 92.3% (3.71) | 0.6232 | 93.5% (3.68) | <0.0001 |
| Yes | 7 (10.8%) | 51.4% (20.38) | 0.0021 to 1.486 | 100% | / | 35.7% (19.79) | 0.0027 to 1.043 |
|
Skin involvement No |
61 (93.8%) | 90.1% (4.76) | 0.0545 | 92.2% (3.77) | 0.6337 | 90.4% (4.11) | 0.0086 |
| Yes | 4 (6.2%) | 66.7% (21.21) | 0.0030 to 12.55 | 100% | / | 37.5% (28.64) | 0.00410 to 3.996 |
|
Preoperative facial pain No |
48 (73.8%) | 94.9% (3.55) | 0.0665 | 92.5% (4.16) | 0.8153 | 90.3% (4.64) | 0.2323 |
| Yes | 17 (26.2%) | 76.9% (12.46) | 0.02882 to 1.672 | 93.7% 6.05 | 0.09260 to 9.327 | 79.1% (11.05) | 0.07614 to 2.408 |
|
Facial nerve involvement No |
54 (83.1%) | 92% (4.56) | 0.0683 | 91.6% (4.04) | 0.4302 | 91.3% (4.19) | 0.0210 |
| Yes | 11 (16.9%) | 81.8% (11.62) | 0.02016 to 3.058 | 100% | / | 68.2% (15.77) | 0.02569 to 1.836 |
|
ENE+ in pN+ patients (n = 11) No |
6 (54.5%) | 53.3% (24.82) | 0.7728 | 41.7% (22.17) | 0.1360 | 62.5% (21.34) | 0.3991 |
| Yes | 5 (45.5%) | 80% (17.88) | 0.1064 to 11.88 | 100% | / | 40% (21.90) | 0.08391 to 2.884 |
|
Stage * I |
17 (26.2%) | 100% | >0.999 | 100% | 0.4142 | 100% | >0.999 |
| II | 22 (33.8%) | 100% | / | 94.4% (5.39) | 0.00345 to 10.32 | 100% | / |
| I | 17 (26.2%) | 100% | >0.999 | 100% | 0.0583 | 100% | >0.999 |
| III | 10 (15.4%) | 100% | / | 80% (12.69) | 0.00339 to 1.103 | 100% | / |
| I | 17 (26.2%) | 100% | 0.0137 | 100% | 0.0854 | 100% | 0.0030 |
| IV | 16 (24.6%) | 54.1% (18.03) | 0.01844 to 0.633 | 82% (11.69) | 0.00493 to 1.414 | 49.9% (13.75) | 0.02344 to 0.464 |
| II | 22 (33.8%) | 100% | >0.999 | 94.4% (5.39) | 0.1414 | 100% | >0.999 |
| III | 10 (15.4%) | 100% | / | 80% (12.69) | 0.01230 to 1.872 | 100% | / |
| II | 22 (33.8%) | 100% | 0.0028 | 94.4% (5.39) | 0.2038 | 100% | 0.0004 |
| IV | 16 (24.6%) | 54.1% (18.03) | 0.00957 to 0.380 | 82% (11.69) | 0.01836 to 2.346 | 49.9% (13.75) | 0.01278 to 0.284 |
| III | 10 (15.4%) | 100% | 0.0590 | 80% (12.69) | 0.7367 | 100% | 0.0260 |
| IV | 16 (24.6%) | 54.1% (18.03) | 0.02995 to 1.068 | 82% (11.69) | 0.1889 to 10.55 | 49.9% (13.75) | 0.03828 to 0.766 |
|
Stage I+II |
39 (59.7%) | 100% | 0.0053 | −1.000 to 1.000 | 0.02 | 100% (4.80) | 0.0007 |
| III+IV | 26 (40.3%) | 72.1% (11.95) | −1.000 to 1.000 | 81.6% (8.37) | 0.02082to 0.832 | 68.4% (10.14) | −1.000 to 1.000 |
|
Margin ** R0 |
43 (66.2%) | 100% | 0.0021 | 94.4% (3.85) | 0.0715 | 100% | 0.0053 |
| R close | 13 (20%) | 75% (15.30) | 8.330 × 10−5 to 0.1243 | 81.8% (11.62) | 0.00625 to 1.237 | 81.4% (11.93) | 0.00024 to 0.234 |
| R0 | 43 (66.2%) | 100% | <0.0001 | 94.4% (3.85) | 0.5780 | 100% | <0.0001 |
| R1 | 9 (13.8%) | 38.8% (28.35) | 2.988 × 10−5 to 0.02052 | 100% | 0.05425 to 185.6 | 40% (17.38) | 0.00010 to 0.014 |
| R close | 13 (20%) | 75% (15.30) | 0.3600 | 81.8% (11.62) | 0.2166 | 81.4% (11.93) | 0.1346 |
| R1 | 9 (13.8%) | 38.8% (28.35) | 0.07117 to 2.612 | 100% | 0.3555 to 95.77 | 40% (17.38) | 0.07128 to 1.425 |
|
Tumour size ** ≤2 |
23 (35.4%) | 95.4% (4.41) | 0.4439 | 100% | 0.1766 | 95.4% (4.41) | 0.2102 |
| >2 and ≤4 | 37 (56.9%) | 84.5% (7.61) | 0.07929 to 3.036 | 90% (5.53) | 0.01939 to 2.065 | 80.8% (7.13) | 0.08102 to 1.739 |
| ≤2 | 23 (35.4%) | 95.4% (4.41) | 0.6336 | 100% | 0.0404 | 95.4% (4.41) | 0.6336 |
| >4 | 5 (7.7%) | 100% | 0.02196 to 530.1 | 80% (17.89) | 3.818 × 10−5 to 0.7971 | 100% | 0.02196 to 530.1 |
| >2 and ≤4 | 37 (56.9%) | 84.5% (7.61) | 0.4436 | 90% (5.53) | 0.4265 | 80.8% (7.13) | 0.3389 |
| >4 | 5 (7.7%) | 100% | 0.1673 to 59.34 | 80% (17.89) | 0.01453 to 5.984 | 100% | 0.2979 to 33.74 |
OS: overall survival; DSS: disease-specific survival; LRFS: local relapse-free survival; DMFS: distant metastasis-free survival; SE: standard error; HR: hazard ratio; CI: confidence interval; LVI: lymphovascular invasion; PNI: perineural invasion. * p value < 0.008 (obtained with Bonferroni’s method) was considered significant. ** p value < 0.0167 (obtained with Bonferroni’s method) was considered significant. Significative p values are underlined.